Contact this trialFirst, we need to learn more about you.
ROCK2 selective inhibitor
Belumosudil for Graft-versus-Host Disease
Recruiting0 awardsPhase 2
New York, New York
This trial tests a new drug to treat chronic graft versus host disease, which affects multiple organs. Belumosudil reduces the immune system response which causes the disease, potentially avoiding the need for other immune-suppressing drugs.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service